Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Akebia Therapeutics's gross profit for the
three
months ended in Mar. 2026 was €35.7 Mil. Akebia Therapeutics's gross profit for the trailing twelve months (TTM) ended in Mar. 2026 was €161.8 Mil.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Akebia Therapeutics had a gross margin of 77.05% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Akebia Therapeutics Gross Profit Related Terms
Akebia Therapeutics Gross Profit Historical Data
* Premium members only.
The historical data trend for Akebia Therapeutics's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:AX9 vs ORGO, EBS, TKNO: Gross Profit Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akebia Therapeutics Gross Profit vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's Gross Profit distribution charts can be found below:
* The bar in red indicates where Akebia Therapeutics's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €161.8 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Akebia Therapeutics (FRA:AX9) has a Gross Profit of €161.8 Mil as of Mar. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Akebia Therapeutics and its competitors.
Is Akebia Therapeutics' Gross Profit too high?
Akebia Therapeutics' current Gross Profit is €161.8 Mil. Overall, Akebia Therapeutics has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' Gross Profit compare to ORGO and EBS?
Akebia Therapeutics' Gross Profit of €161.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Drug Manufacturers company?
A good Gross Profit depends on the Drug Manufacturers industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Akebia Therapeutics and its competitors. Akebia Therapeutics's current Gross Profit is €161.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (FRA:AX9) is currently considered Fairly Valued. The stock's GF Value™ is €1.11, compared to a current price of €1.15 — trading 3.3% above its estimated fair value. The current Gross Profit is €161.8 Mil. Akebia Therapeutics' overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Akebia Therapeutics (FRA:AX9), the current Gross Profit is €161.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akebia Therapeutics (FRA:AX9) Overvalued in 2026?
Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be overvalued.
The current stock price of €1.15 is trading 3.3% above its estimated GF Value™ of €1.11.
GuruFocus considers Akebia Therapeutics to be Fairly Valued.
Key valuation signals for FRA:AX9:
Gross Profit: €161.8 Mil
GF Value™: €1.11 vs. price of €1.15 (3.3% above fair value)
No single metric tells the full story. See the FRA:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
54GF Score
Get the complete analysis for FRA:AX9
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AX9 has been successfully added to your 
